Biosyent Inc. (CVE:RX) is scheduled to announce its earnings results before the market opens on Thursday, August 10th. Analysts expect the company to announce earnings of $0.09 per share for the quarter.

Biosyent (CVE:RX) last issued its quarterly earnings results on Thursday, May 25th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by $0.02. Biosyent had a return on equity of 21.00% and a net margin of 23.59%. The company had revenue of $3.82 million during the quarter, compared to the consensus estimate of $4.80 million.

WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at

About Biosyent

BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Receive News & Ratings for Biosyent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent Inc. and related companies with's FREE daily email newsletter.